Research programme: glucose transporter type 1 inhibitors - IOmet Pharma

Drug Profile

Research programme: glucose transporter type 1 inhibitors - IOmet Pharma

Alternative Names: GLUT 1 inhibitors - IOmet Pharma; IOM1; IOM2; IOM3; IOM4

Latest Information Update: 04 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IOmet Pharma
  • Class Small molecules
  • Mechanism of Action Glucose transporter type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 16 Apr 2016 Pharmacodynamics data from a preclinical studies in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 11 Jan 2016 IOmet Pharma has been acquired by Merck & Co
  • 01 Mar 2014 Preclinical trials in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top